Indonesia's Bio Farma aims to submit interim review on Sinovac vaccine in January


A health worker holds up a vial containing Sinovac's Covid-19 candidate vaccine on Aug. 8, 2020 at the Sao Lucas Hospital in Porto Alegre, Brazil.- Reuters

JAKARTA (The Jakarta Post Jakarta/ANN): PT Bio Farma has announced that the state-owned pharmaceutical company plans to submit its interim results from the third and final trial phase of the Sinovac vaccine to the Indonesian Food and Drug Monitoring Agency (BPOM) in January 2021.

The interim report is to include the results of the phase three clinical trials of the vaccine conducted in China and Brazil, which started prior to the trials in Indonesia.

Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.

Monthly Plan

RM13.90/month

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Indonesia , China , covid-19 , Biopharma , Sinovac

   

Next In Aseanplus News

Two local men arrested over firebombing of entertainment outlet in Jalan Yap Kwan Seng
India court details sexual harassment charges against former wrestling body chief
Entrepreneur Development Minister urges Sabahans to register as Co-opbank Pertama members
Binance registers with India's financial watchdog as it seeks to resume operations
Akhimullah gets early goal as Malaysia beat South Korea
KKB polls: Go out to vote with peace of mind as safety assured, says s'gor police
Asean News Headlines at 10pm on Friday (May 10, 2024)
‘Singapore will be in good hands under the 4G team’: PM Lee Hsien Loong, after chairing final Cabinet meeting
Malaysia ready to strengthen ties with S'pore under incoming PM, Lawrence Wong, says Anwar
RM45.85 million: May 9 Toto prize money largest ever won on a single ticket in Singapore

Others Also Read